基于收入的公共药物保险扣除额对坚持服用喘药物的影响
Kate M Johnson1, Lucy Cheng2, Yiwei Yin3
1Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada; Division of Respiratory Medicine, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
概括
公共药物计划的基于收入的扣除金减少了公共支出,但没有影响低收入人群对喘药物的坚持或使用. 这表明节约成本的措施可能不会影响患者喘管理的结果.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 制药经济学 制药经济学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 与成本相关的不坚持药物治疗是有效喘管理的重要障碍.
- 了解对药物获取的财务影响对于公共卫生战略至关重要.
研究的目的:
- 量化公共药物计划扣除额对喘药物的坚持的影响.
- 评估基于收入的扣除门如何影响喘患者的药物使用和患者费用.
主要方法:
- 在不列颠哥伦比亚省 (2013-2018) 用准实验性的回归不连续性分析来评估可扣除的门 (15,000美元和30,000美元).
- 使用药物记录来评估药物成本,使用,控制器对总药物比率,短期β-agonist过度使用,以及控制器疗法所覆盖的日数比例.
主要成果:
- 15,000美元的可扣除门将公共药品成本降低了28%,但患者成本增加了48.45美元.
- 3万美元的可扣除门也使患者费用增加了11% (27.65美元),但没有显著影响公共药物费用.
- 任何可扣除的门都没有影响喘药物的使用,坚持或过度使用缓解疗法.
结论:
- 基于收入的自扣额有效地减少了公共药物支出.
- 这些自扣额不会对低收入人群的喘药物坚持或治疗结果产生负面影响.
- 政策影响表明,在不影响基本喘药物获取的情况下,有可能节省成本.
相关概念视频
Inhaled Medications
288
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
288
Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324


